FIA
ALXN

FNY Investment Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

FNY Investment Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-55
Closed -$6K – 986
2020
Q3 		$6K Sell
55
-10
-15% -$1.08K ﹤0.01% 367
2020
Q2 		$7K Buy
+65
New +$6.9K ﹤0.01% 303
2018
Q3 		– Sell
-33
Closed -$4K – 1406
2018
Q2 		$4K Buy
+33
New +$3.86K ﹤0.01% 671

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

FNY Investment Advisers's ALXN Position: Q3 2021 in Review

FNY Investment Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 48,439 shares — an estimated $8.9M sold.

FNY Investment Advisers first reported a position in ALXN in Q3 2018 and held it in 7 quarters. The position peaked at $8.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • FNY Investment Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 48,439 Alexion Pharmaceuticals shares in Q3 2021, an estimated $8.9M.
  • FNY Investment Advisers first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 7 quarters.
  • FNY Investment Advisers's Alexion Pharmaceuticals position peaked at $8.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on FNY Investment Advisers's 13F filing for Q3 2021, filed 13 Oct 2021.